Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer (MECCA)
A Phase 3 Randomized Controlled Study of Metronomic Capecitabine Combined With Aromatase Inhibitor Versus Aromatase Inhibitor Alone for First Line Treatment in Hormone Receptor-positive, Her2-negative Metastatic Breast Cancer
Sponsor: Sun Yat-Sen University Cancer Center
Listed as NCT02767661, this PHASE3 trial focuses on Breast Cancer and remains completed. Sponsored by Sun Yat-Sen University Cancer Center, it has been updated 11 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Mar 2026 — Present [monthly]
Completed PHASE3
-
Feb 2026 — Mar 2026 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2024 — Feb 2026 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 6 earlier versions
-
Feb 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Feb 2023 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Recruiting PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2017 — Jun 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sun Yat-Sen University Cancer Center
- Sun Yat-sen University
For direct contact, visit the study record on ClinicalTrials.gov .